摘要
肺炎支原体(MP)是引起儿童呼吸道感染的常见病原体之一。学龄前、学龄儿童由MP感染而引起的MP肺炎相对多见,且发病率日益增高。近年来在MP感染的治疗方面虽然取得了很大进展,但MP对大环内酯类抗生素的耐药问题给临床治疗带来了一定的难度。本文就有效治疗MP感染的研究进展作一阐述。
Mycoplasma pneumoniae is one of the main etiologic agents of respiratory tract infection in children. In recent years, the annual specific incidence rate of mycoplasma pneumoniae infection of children especially among infants has been greatly increasing. Comprehensive measures are necessary to the treatments of mycoplasma pneumoniae infection, which includes four aspects, general and symptomic therapy, using of antibiotic and glucocorticoid, treatment for extra-pulmonary complications. This article just reviewed the recent advancements in the study of new and effective therapy of mycoplasma pneumoniae infection.
出处
《世界临床药物》
CAS
2009年第4期237-241,共5页
World Clinical Drug
关键词
感染
肺炎支原体
儿童
耐药
难治性
infection
mycoplasma pneumoniae
children
drug resistance
refractory
